NCT05128487: A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the study
Exclusions: Patients with active untreated brain metastasis or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT05128487

Comments are closed.

Up ↑